Heart Failure With Preserved Ejection Fraction Clinical Trial
— HFpEF-CMDOfficial title:
Distribution and Clinical Implication of Coronary Flow Reserve and Index of Microcirculatory Resistance in Patients With Heart Failure With Preserved Ejection Fraction Without Significant Coronary Artery Disease
To evaluate the incidence of coronary microvascular dysfunction (CMD) and its' prognostic implication in patients who have diagnosed as heart failure with preserved ejection fraction (HFpEF) confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease.
| Status | Recruiting |
| Enrollment | 100 |
| Est. completion date | December 31, 2024 |
| Est. primary completion date | September 30, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 19 Years and older |
| Eligibility | Inclusion Criteria: - Subject must be at least 19 years of age. - Subject with preserved ejection fraction (ejection fraction > 50%) - Subject presented with dyspnea on exertion (NYHA Grade 2 or more) and diagnosed as HFpEF using HFA-PEFF scoring system (HFA-PEFF =5 or 2-4 with abnormal stress test or invasive hemodynamic test) - Subject who clinically need coronary angiography - Subject who is able to voluntarily sign informed consent form Exclusion Criteria: - Subject with reduced ejection fraction (<50%) - Subject with significant coronary artery stenosis on coronary angiography (diameter stenosis =90% or 50-90% with fractional flow reserve [FFR] =0.80) - Subject who has other obvious causes of dyspnea (ex, lung disease) - Subject who have non-cardiac co-morbid conditions with life expectancy <1 year |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Samsung Medical Center | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Samsung Medical Center |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Proportion of CMD in patients with HFpEF | Proportion of CMD confirmed by invasive physiologic evaluation | Immediate after the index procedure | |
| Secondary | Correlation between CMD and left ventricular end diastolic pressure | Correlation between CMD confirmed by invasive physiologic evaluation and left ventricular end diastolic pressure | Immediate after the index procedure | |
| Secondary | Correlation between CMD and E/e' | Correlation between CMD confirmed by invasive physiologic evaluation and E/e' | Immediate after the index procedure | |
| Secondary | Correlation between CMD and HFA-PEFF score | Correlation between CMD confirmed by invasive physiologic evaluation and HFA-PEFF score | Immediate after the index procedure | |
| Secondary | Correlation between CMD and NT-proBNP | Correlation between CMD confirmed by invasive physiologic evaluation and NT-proBNP | Immediate after the index procedure | |
| Secondary | Correlation between CMD and pulmonary artery wedge pressure | Correlation between CMD confirmed by invasive physiologic evaluation and pulmonary artery wedge pressure | Immediate after the index procedure | |
| Secondary | Correlation between CMD and mean pulmonary artery pressure | Correlation between CMD confirmed by invasive physiologic evaluation and mean pulmonary artery pressure | Immediate after the index procedure | |
| Secondary | All-cause death | All-cause death during follow-up | At 2 years after the index procedure | |
| Secondary | Cardiac death | Cardiac death during follow-up | At 2 years after the index procedure | |
| Secondary | Myocardial infarction | Myocardial infarction during follow-up | At 2 years after the index procedure | |
| Secondary | Any revascularization | Any revascularization during follow-up | At 2 years after the index procedure | |
| Secondary | Readmission due to heart failure | Readmission due to heart failure during follow-up | At 2 years after the index procedure | |
| Secondary | Readmission | Readmission during follow-up | At 2 years after the index procedure | |
| Secondary | Proportion of heart failure with reduced ejection fraction | Proportion of progression of heart failure with reduced ejection fraction | At 2 years after the index procedure | |
| Secondary | Correlation between CMD and Excercise induced E/e' | Correlation between CMD confirmed by invasive physiologic evaluation and exercise induced E/e' | Immediate after the index procedure | |
| Secondary | Correlation between CMD and Exercise induced pulmonary artery wedge pressure | Correlation between CMD confirmed by invasive physiologic evaluation exercise induced and pulmonary artery wedge pressure | Immediate after the index procedure | |
| Secondary | Correlation between CMD and exercise time | Correlation between CMD confirmed by invasive physiologic evaluation exercise time | Immediate after the index procedure | |
| Secondary | Correlation between CMD and mean exercise induced pulmonary artery pressure | Correlation between CMD confirmed by invasive physiologic evaluation and exercise induced mean pulmonary artery pressure | Immediate after the index procedure | |
| Secondary | Correlation between CMD and Gas analysis data (Peak exercise oxygen consumption, Respiratory quotient) | Correlation between CMD confirmed by invasive physiologic evaluation and exercise induced peak exercise oxygen consumption, Respiratory quotient | Immediate after the index procedure |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
| Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
| Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
| Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
| Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
| Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
| Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
| Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
| Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
| Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
| Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
| Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
| Recruiting |
NCT03550235 -
Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
|
||
| Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
| Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
| Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
| Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
| Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
| Withdrawn |
NCT05322616 -
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
|
Phase 1 |